Key Topics in Influenza from the 12th Annual World Vaccine Congress

The 12th Annual World Vaccine Congress, held this year in Lyon, France, October 4-7, featured an impressive roster of speakers, delegates, and exhibitors representing a wide range of specialties, research interests, healthcare organizations, and vaccine manufacturers. The program featured experts in virology, public health, epidemiology, immunology, and vaccine research and manufacturing who covered the latest news and developments in several categories of infectious disease, including influenza.

HCPLive was there to cover the event, with daily reports and summaries of several key sessions. Below are links to recaps of sessions from the 12th Annual World Vaccine Congress that focused on influenza vaccines.

Nasal Influenza Vaccine Shows Promise for Cross-immunity

Early positive clinical trial results for a novel nasal influenza vaccine.

How Should We Manage the H1N1 Post-pandemic Period?

Vaccine expert says that there are many lessons to be learned from the response to the most recent H1N1 pandemic.

Clinical Trials Pave the Way for Single-dose Flu Immunization

Researchers studying influenza vaccines were able to achieve immune response with a single vaccination against H1N1.

New Nasal Spray Influenza Vaccine May Enable Rapid Pandemic Response

Safe and effective new nasal spray-delivered influenza vaccine could be produced quickly in high quantities during a pandemic infection.

BARDA is on the Frontlines of the Global Battle against Flu

How a massive operation of medical countermeasures was mobilized to tackle the ever-present threat of influenza in the US and overseas.

Purified Protein Vaccines, Recombinant DNA Technology, and H5N1

New vaccine would be the first cell-derived, recombinant protein-based influenza vaccine licensed in the US.